Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 03 04:00PM ET
3.96
Dollar change
+0.32
Percentage change
8.93
%
Index- P/E- EPS (ttm)-6.50 Insider Own- Shs Outstand0.91M Perf Week3.37%
Market Cap3.63M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float0.65M Perf Month-1.00%
Income-5.46M PEG- EPS next Q- Inst Own1.84% Short Float1.34% Perf Quarter-32.91%
Sales0.00M P/S- EPS this Y- Inst Trans-37.81% Short Ratio0.36 Perf Half Y-40.98%
Book/sh4.37 P/B0.91 EPS next Y- ROA-211.58% Short Interest0.01M Perf Year-48.10%
Cash/sh4.47 P/C0.89 EPS next 5Y- ROE-368.99% 52W Range3.51 - 14.80 Perf YTD-51.94%
Dividend Est.- P/FCF- EPS past 5Y62.48% ROI-136.73% 52W High-73.21% Beta1.09
Dividend TTM- Quick Ratio12.22 Sales past 5Y- Gross Margin-775.00% 52W Low12.96% ATR (14)0.38
Dividend Ex-Date- Current Ratio12.22 EPS Y/Y TTM- Oper. Margin- RSI (14)47.95 Volatility12.22% 9.84%
Employees4 Debt/Eq0.00 Sales Y/Y TTM-98.99% Profit Margin-136525.00% Recom- Target Price27.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-8.40% Payout- Rel Volume1.51 Prev Close3.64
Sales Surprise- EPS Surprise- Sales Q/Q-100.00% Earnings- Avg Volume24.48K Price3.96
SMA200.51% SMA50-9.91% SMA200-33.37% Trades Volume37,028 Change8.93%
Date Action Analyst Rating Change Price Target Change
Jun-26-19Initiated Maxim Group Buy $4
Nov-10-17Downgrade ROTH Capital Buy → Neutral
Nov-27-24 04:05PM
Aug-19-24 04:11PM
Aug-15-24 10:53PM
May-16-24 08:54AM
Jan-25-24 04:29PM
04:15PM Loading…
Dec-28-23 04:15PM
Nov-14-23 07:23PM
Oct-16-23 04:37PM
Sep-18-23 07:30AM
Aug-28-23 12:44PM
Aug-15-23 08:46AM
Jul-27-23 07:30AM
Jan-27-23 07:00AM
Dec-15-22 07:00AM
Dec-12-22 07:49AM
05:35AM Loading…
Nov-17-22 05:35AM
Aug-16-22 10:53AM
Jul-11-22 08:00AM
Jul-09-22 09:07AM
Jul-05-22 08:00AM
Jun-10-22 08:00AM
Apr-25-22 01:29PM
Feb-02-22 12:27PM
08:45AM
Dec-21-21 08:00AM
Nov-08-21 04:15PM
Nov-05-21 04:30PM
Oct-25-21 07:15AM
Oct-12-21 08:00AM
Aug-20-21 02:52PM
09:34AM Loading…
Aug-04-21 09:34AM
Jun-23-21 08:00AM
Mar-31-21 04:30PM
Feb-01-21 07:30AM
Jan-15-21 09:15AM
Dec-16-20 08:00AM
Dec-01-20 04:56AM
Nov-30-20 12:50PM
Nov-16-20 08:45AM
Nov-02-20 08:00AM
Oct-30-20 08:14AM
Oct-28-20 03:00PM
08:00AM
Oct-26-20 06:30AM
Oct-15-20 08:00AM
Sep-24-20 09:00AM
Sep-18-20 04:45PM
Sep-16-20 01:05PM
Sep-15-20 08:30AM
Sep-14-20 08:30AM
Aug-26-20 05:45AM
Aug-14-20 08:45AM
Aug-10-20 04:30PM
Jul-08-20 08:00AM
Jun-24-20 08:00AM
Jun-16-20 08:00AM
Jun-01-20 05:20AM
May-15-20 08:45AM
May-11-20 04:03PM
Apr-09-20 06:15AM
Apr-02-20 09:47PM
Mar-31-20 12:43PM
Mar-30-20 04:03PM
02:30PM
Mar-26-20 08:00AM
Mar-05-20 09:00AM
Feb-18-20 08:55AM
Jan-13-20 08:00AM
Jan-07-20 09:15AM
Dec-30-19 08:00AM
Dec-17-19 10:30AM
Dec-04-19 01:22PM
Dec-03-19 09:00AM
Nov-25-19 05:15AM
Nov-14-19 04:03PM
Nov-07-19 04:30PM
Oct-22-19 08:00AM
Oct-18-19 10:23AM
Oct-16-19 09:20AM
Oct-01-19 08:00AM
Sep-18-19 08:00AM
Aug-30-19 08:01PM
Aug-23-19 11:30AM
Aug-17-19 09:59AM
Aug-16-19 07:33AM
Aug-14-19 04:03PM
07:32AM
Aug-09-19 05:00PM
Aug-07-19 09:15AM
Jul-09-19 09:00AM
Jul-03-19 10:54AM
Jun-26-19 09:10AM
Jun-04-19 07:00AM
May-29-19 02:15PM
May-23-19 08:10AM
May-15-19 04:08PM
04:03PM
May-13-19 07:00AM
May-08-19 08:00PM
May-06-19 03:12PM
Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, proNeura. Its lead product is probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo on February 7, 1992 and is headquartered in South San Francisco, CA.